TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE) filed its financial and operating results today for the fourth quarter and the year ended March 31, 2014.
Antibe’s highlights for the fiscal year included:
- Successfully closing its initial public offering and listing on the TSX Venture Exchange.
- Achieving the maximum raise under the IPO and conducting additional non-brokered private placements bringing the total capital raised in the fiscal year to $7.4M.
- Completing the planned GLP pre-clinical program for its lead drug, ATB-346, to support clinical studies in humans within the timeframe set out in the prospectus.
Subsequent to its fiscal year-end, the Corporation received approval from Health Canada to begin studies in humans, and started its Phase I clinical trial in June, 2014.
The Corporation’s audited year-end financial statements and MD&A have been filed on SEDAR.
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and inflammation. These medicines are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body, to regulate a range of fundamental cellular processes. The company's drug design approach involves chemically linking an existing off-patent drug to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation or pain, this approach can efficiently produce improved versions of existing drugs.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.